Article info

PDF
Opinion
Use of intravenous hyoscine butylbromide (Buscopan) during gastrointestinal endoscopy

Authors

  • Thomas Lee Gastroenterology, Northumbria Healthcare NHS Foundation Trust, UKNorthern Region Endoscopy Group (NREG), Newcastle, UK PubMed articlesGoogle scholar articles
  • John Anderson Department of Gastroenterology, Cheltenham General Hospital, Cheltenham, UKBowel Cancer Screening Programme Accreditation Panel, London, UK PubMed articlesGoogle scholar articles
  • Siwan Thomas-Gibson Wolfson Unit for Endoscopy, St Mark's Hospital, London, UKSurgery, Imperial College, London, UKJoint Advisory Group (on Gastrointestinal Endoscopy), London, UK PubMed articlesGoogle scholar articles
  • Colin Rees Northern Region Endoscopy Group (NREG), Newcastle, UKDepartment of Gastroenterology, South Tyneside General Hospital, South Shields, UKBritish Society of Gastroenterology, London, UKNorthern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK PubMed articlesGoogle scholar articles
  • Google scholar articles
  1. Correspondence to Dr Thomas Lee; tom.lee{at}nhct.nhs.uk
View Full Text

Citation

Lee T, Anderson J, Thomas-Gibson S On behalf of the British Society of Gastroenterology, Joint Advisory Group on Gastrointestinal Endoscopy and Bowel Cancer Screening Programme, et al
Use of intravenous hyoscine butylbromide (Buscopan) during gastrointestinal endoscopy

Publication history

  • Received 4 July 2017
  • Revised 25 July 2017
  • Accepted 25 July 2017
  • Published in print 17 August 2017.
  • Published online 18 August 2017.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.